For the First Time Since TC Heartland, the Federal Circuit Addresses Venue in an ANDA Case – the Holding May Also Impact BPCIA Litigation 

On November 5, 2020, in Valeant Pharms. N. Am. LLC  v. Mylan Pharms. Inc., No. 2019-2402, the Federal Circuit held that venue in Hatch-Waxman cases brought under 35 U.S.C. § 271(e)(2)(A) is proper “only in districts where actions related to the submission of an Abbreviated New Drug Application (‘ANDA’) occur, not in all locations where future distribution of the generic products specified in the ANDA is contemplated.”  Slip op. at 3.  If the ruling stands, it will restrict venue available against domestic generic drug makers in ANDA cases, and may similarly impact venue in litigation under the Biologics Price Competition and Innovation Act (“BPCIA”).

In TC Heartland LLC v. Kraft Foods Grp. Brands LLC, 137 S. Ct. 1514 (2017), the Supreme Court “held that the general venue provision in 28 U.S.C. § 1391—which provides that a corporation is deemed to ‘reside’ in any judicial district in which it is subject to personal jurisdiction—does not modify the term ‘resides’ in 28 U.S.C. § 1400, the more specific venue statute applicable to patent cases.” Valeant Slip op. at 2. As a result, “a [domestic] corporation may be sued for patent infringement [only] in . . . the state in which it is incorporated and . . . [the state(s) in which] it has a regular and established place of business and an act of infringement has occurred.” Id.

Valeant is the Federal Circuit’s first decision addressing the impact of TC Heartland on venue in ANDA proceedings. Under the patent venue statute, 28 U.S.C. § 1400(b), to determine “whether venue is proper in a district other than one in a state in which a defendant is incorporated, a court must determine . . . ‘where the defendant has committed acts of infringement.’” Id. at 8 (quoting 28 U.S.C. § 1400(b)). ANDA cases are unique among patent litigations because the act of infringement is the submission of an application to the FDA to market a generic drug in the future, rather than making, using, offering to sell, selling, or importing a patented product. See 35 U.S.C. § 271(e) (2). The question before the Federal Circuit in Valeant was whether the act of infringement identified in the patent venue statute “occurs only when and where an ANDA-filer submits its ANDA to the FDA or occurs wherever future distribution of the generic is contemplated.” Slip op. at 9.

Click here to read more.



WSG Member: Please login to add your comment.